X4 Pharmaceuticals, Inc. Forecasted to Post Q1 2024 Earnings of ($0.22) Per Share (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Research analysts at Zacks Small Cap issued their Q1 2024 earnings per share estimates for shares of X4 Pharmaceuticals in a note issued to investors on Tuesday, April 2nd. Zacks Small Cap analyst D. Bautz forecasts that the company will post earnings per share of ($0.22) for the quarter. The consensus estimate for X4 Pharmaceuticals' current full-year earnings is ($0.52) per share. Zacks Small Cap also issued estimates for X4 Pharmaceuticals' FY2024 earnings at ($0.57) EPS and FY2025 earnings at ($0.37) EPS.

A number of other analysts also recently weighed in on XFOR. HC Wainwright restated a "buy" rating and issued a $3.00 target price on shares of X4 Pharmaceuticals in a research report on Friday, March 22nd. B. Riley downgraded X4 Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $3.00 to $1.00 in a research report on Tuesday, December 12th.

X4 Pharmaceuticals Price Performance

NASDAQ:XFOR traded down $0.10 during mid-day trading on Friday, reaching $1.37. The stock had a trading volume of 1,871,142 shares, compared to its average volume of 2,069,930. The firm has a 50 day moving average price of $1.03 and a two-hundred day moving average price of $0.90. The stock has a market capitalization of $230.08 million, a P/E ratio of -2.28 and a beta of 0.49. X4 Pharmaceuticals has a one year low of $0.57 and a one year high of $2.58. The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.34 and a current ratio of 5.34.

Insiders Place Their Bets

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 27,721 shares of X4 Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $1.01, for a total value of $27,998.21. Following the transaction, the chief financial officer now directly owns 52,500 shares of the company's stock, valued at approximately $53,025. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 27,721 shares of X4 Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $1.01, for a total value of $27,998.21. Following the transaction, the chief financial officer now directly owns 52,500 shares of the company's stock, valued at approximately $53,025. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Paula Ragan sold 49,678 shares of the business's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $0.88, for a total value of $43,716.64. Following the transaction, the chief executive officer now directly owns 765,068 shares in the company, valued at $673,259.84. The disclosure for this sale can be found here. Insiders have sold 185,708 shares of company stock valued at $170,428 in the last ninety days. Company insiders own 1.08% of the company's stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several hedge funds have recently made changes to their positions in XFOR. BlackRock Inc. increased its stake in shares of X4 Pharmaceuticals by 2,547.2% during the second quarter. BlackRock Inc. now owns 9,095,274 shares of the company's stock valued at $17,645,000 after buying an additional 8,751,694 shares during the period. Stonepine Capital Management LLC purchased a new position in shares of X4 Pharmaceuticals during the second quarter valued at approximately $8,934,000. Perceptive Advisors LLC purchased a new position in shares of X4 Pharmaceuticals during the first quarter valued at approximately $3,955,000. Bain Capital Life Sciences Investors LLC increased its stake in shares of X4 Pharmaceuticals by 30.8% during the second quarter. Bain Capital Life Sciences Investors LLC now owns 15,960,588 shares of the company's stock valued at $30,964,000 after buying an additional 3,758,078 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of X4 Pharmaceuticals by 348.6% during the third quarter. Vanguard Group Inc. now owns 3,208,103 shares of the company's stock valued at $5,486,000 after purchasing an additional 2,492,928 shares in the last quarter. 72.03% of the stock is owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.